Completed PHASE1 INTERVENTIONAL 7-arm NCT00705874

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

A Phase I Open Label, Multicenter, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Dose Limiting Toxicity, Safety and Pharmacokinetics of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Sponsor: Progen Pharmaceuticals

Conditions Cancer

Interventions CGC-11047 and 5-flurouracil / leucovorin CGC-11047 and bevacizumab CGC-11047 and cisplatin CGC-11047 and docetaxel CGC-11047 and erlotinib CGC-11047 and gemcitabine CGC-11047 and sunitinib

Updated 8 times since 2017 Last updated: Jun 21, 2016 Started: May 31, 2006 Primary completion: Aug 31, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Cancer, this trial is completed. The trial is conducted by Progen Pharmaceuticals and has accumulated 8 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Progen Pharmaceuticals

Data source: Progen Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Dallas, United States , Denver, United States , Greenville, United States , Indianapolis, United States , Kettering, United States , Las Vegas, United States , Norfolk, United States , Ocoee, United States , Tyler, United States and 2 more locations